BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, July 15, 2025
Home » Newsletters » BioWorld

BioWorld

Feb. 6, 2017

View Archived Issues

Amgen buoyed on Repatha cardiovascular data, positive fourth-quarter earnings

Estimate-beating fourth-quarter earnings for Amgen Inc. pushed company shares about $7.95 higher to close at $167.53 on Friday as sales of its cholesterol treatment Repatha (evolocumab) rose and a closely watched phase III trial suggested that combining the antibody with optimized statin treatment could reduce the risk of heart attack and other CV events in patients with arterial plaque buildups. Read More

Through the 'Portola': See submarine sandwich grow $150M meatier via Royalty

Portola Pharmaceuticals Inc.'s chief financial officer, Mardi Dier, told BioWorld Today the deal with Healthcare Royalty Partners (HCRP) was "exactly what we planned to do" – add "part two" to the "part one" of nondilutive funding late last year, when the company signed a $50 million loan agreement with longtime partners Bristol-Myers Squibb Co. (BMS) and Pfizer Inc. for more resources to develop factor Xa inhibitor antidote Andexxa (andexanet alfa). Read More

Seroba raises $108M in first close of third fund

DUBLIN – The "strong performance" of its second life sciences fund was key to Seroba Life Sciences raising a third. The Dublin-based venture capital firm has raised €100 million (US$108 million) in a first close, but it remains open to additional investments for much of this year. Read More

Dual targeting drug fights Myc-driven tumors

It is pretty much a cliché that the future of oncology lies in combination treatments, albeit a cliché with a lot of truth to it. Combinations, though, bring their own challenges. In many cases, efficacy and toxicity increase in lockstep, and in the context of clinical trial design, "endless possibilities" is a bug, not a feature. Read More

Taiwan's Senhwa tackles cholangiocarcinoma, gets orphan status from FDA

TAIPEI, Taiwan – Calling its recent FDA orphan designation for small-molecule drug CX-4945 in cholangiocarcinoma an important milestone in its development and regulatory strategy, 2012 startup Senhwa Biosciences Inc. enters 2017 with plans for an uplisting on the Taiwan stock exchange and hopes for restoring investor enthusiasm for Taiwan's biopharma sector. Read More

Financings

Neos Therapeutics Inc., of Grand Prairie, Texas, said it priced an underwritten public offering of 5 million shares of its common stock at $5 each for gross proceeds of $25 million. Read More

Other news to note

Asterias Biotherapeutics Inc., of Fremont, Calif., said it is extending the expiration date of certain warrants to purchase up to an aggregate of 3.3 million shares of series A common stock with a par value of $0.0001 per share. Read More

Appointments and advancements

X4 Pharmaceuticals Inc., of Cambridge, Mass., named Sudha Parasuraman chief medical officer. Read More

In the clinic

Neovacs SA, of Paris, said its independent data and safety monitoring board allowed the company to continue the phase IIb trial testing lead candidate IFNalpha Kinoid for the treatment of lupus. Read More

Bench Press: BioWorld looks at translational medicine

The response to stress is controlled by the hypothalamic-pituitary-adrenal (HPA) axis, and dysfunction of the HPA axis induced by chronic stress puts individuals at risk of a variety of psychiatric as well as physiological conditions. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 14, 2025.
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • AI-generated illustration of CAR T cells

    Researchers arm CAR T cells to fight solid tumors

    BioWorld
    Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing